- Moderna Inc (NASDAQ: MRNA) has received emergency use approval for its mRNA COVID-19 vaccine in Japan.
- Takeda Pharmaceutical Co Ltd (NYSE: TAK), which is in deal with Moderna, will begin the vaccine distribution in Japan immediately.
- Moderna’s COVID-19 vaccine is authorized for emergency use in adults aged 18 years and older.
- The latest approval is based on Moderna’s Phase 3 COVE study results and positive initial clinical data from the Takeda-led placebo-controlled Phase 1/2 study.
- The results showed an immune response consistent with Moderna’s pivotal Phase 3 COVE trial conducted in the U.S.
- Previously, the companies had announced that Takeda would handle about 50 million Moderna doses, beginning in the first half of 2021.
- It was also affirmed discussions for an additional potential supply of 50 million doses from the beginning of 2022.
- Price Action: MRNA shares are up 1.6% at $168.61, and TAK shares are up by 0.92% at $17.48 during the premarket session on the last check Friday.
Clearside Biomedical Announces Safety Results From Cohort 1 Of OASIS Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD; Primary Endpints In Cohort 1 Were Achieved
- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events -
- Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 -
ALPHARETTA, Ga., June
